Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report.
about
Is personality a key predictor of missing study data? An analysis from a randomized controlled trialEvaluating genetic markers and neurobiochemical analytes for fluoxetine response using a panel of mouse inbred strainsFluoxetine treatment of alcoholic perpetrators of domestic violence: a 12-week, double-blind, randomized, placebo-controlled intervention studyBiological predictors of pharmacological therapy in anxiety disordersIntermediate phenotypes and biomarkers of treatment outcome in major depressive disorderA Randomized Controlled Trial of Mindfulness-Based Cognitive Therapy for Treatment-Resistant Depression.Predictors of attrition during one year of depression treatment: a roadmap to personalized interventionTreatment-resistant depression in primary care across CanadaPreconsent education about research processes improved African Americans' willingness to participate in clinical research.The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review.Predicting complete loss to follow-up after a health-education program: number of absences and face-to-face contact with a researcher.Biomarkers to predict antidepressant responseQuality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up.The development of the DSM-5 Cultural Formulation Interview-Fidelity Instrument (CFI-FI): a pilot study.Early adverse events and attrition in selective serotonin reuptake inhibitor treatment: a suicide assessment methodology study report.Impact of motivational pharmacotherapy on treatment retention among depressed LatinosAdherence and persistence with branded antidepressants and generic SSRIs among managed care patients with major depressive disorderA new paradigm for the prediction of antidepressant treatment responseDesign and inference for the intent-to-treat principle using adaptive treatment.The long-term trajectory of depression among Latinos in primary care and its relationship to depression care disparities.Depression Screening and Education: Options to Reduce Barriers to Treatment (DESEO): protocol for an educational intervention study.Factors associated with non-completion in a double-blind randomized controlled trial of olanzapine plus sertraline versus olanzapine plus placebo for psychotic depression.Sampling bias in an internet treatment trial for depression.Sex differences in response to citalopram: a STAR*D report.Retention and attrition among African Americans in the STAR*D study: what causes research volunteers to stay or stray?Factors associated with attrition from a randomized controlled trial of meaning-centered group psychotherapy for patients with advanced cancerRace, genetic ancestry and response to antidepressant treatment for major depressionAn open pilot study of the combination of escitalopram and bupropion-SR for outpatients with major depressive disorderPredictors of premature discontinuation of treatment in multiple disease statesUse of clinical neurophysiology for the selection of medication in the treatment of major depressive disorder: the state of the evidence.Are antidepressants effective in the treatment of postpartum depression? A systematic review.Pharmacogenetics of antidepressants, mood stabilizers, and antipsychotics in diverse human populations.Quality of life and functioning of Hispanic patients with Major Depressive Disorder before and after treatment.Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks.ANTIDEPRESSANT ADHERENCE ACROSS DIVERSE POPULATIONS AND HEALTHCARE SETTINGS.Intrinsic functional connectivity in late-life depression: trajectories over the course of pharmacotherapy in remitters and non-remitters.What predicts attrition in second step medication treatments for depression?: a STAR*D Report.Toward a cultural adaptation of pharmacotherapy: Latino views of depression and antidepressant therapy.Magnetic seizure therapy in treatment-resistant depression: clinical, neuropsychological and metabolic effects.Duration of antidepressant drug treatment and its influence on risk of relapse/recurrence: immortal and neglected time bias.
P2860
Q24288800-EC6C6013-D3F3-4C3E-9AB0-05769E0E37BFQ24632901-972CCABD-4465-452C-9DAF-FBE629829E9CQ24633596-2D18A142-9180-4323-BE97-F7BEAD781A2BQ26781100-21C775A5-ABAB-40FD-97C3-A660F38AA6C1Q26823991-ED30F4AD-D0BD-4464-8A97-4630808D5276Q30383857-AD1FD120-7F16-4D37-8F5C-4745573101AAQ33836094-8CD20BB6-AB9E-40BE-9644-5F5893CFC2F7Q33861601-83B87E0B-3E65-4F8E-AA5F-84633038F80DQ33941929-3555245A-3174-4FDD-8D82-46C74DB79F71Q34021977-4D03E9F0-EA1B-4F31-A64E-1134E6A4E8E2Q34060042-BE77BADE-E739-4EA4-B49E-42A9F8DEC647Q34247513-0DCE7D5F-FFF2-429B-99CF-DB282DBFDA3AQ34713784-937A3F17-6408-44F1-90E7-06743B165A8AQ35012786-905161D3-87AE-4774-8D54-BE2505FF54ACQ35058467-6C0773B8-A806-4DB5-A11B-2A92484A5F23Q35090784-C1EC0C52-C199-44BB-8749-0594C6BC83ADQ35205431-2E43DC05-A93B-4087-AEE3-E79E986450F0Q35237120-D274D233-D9E5-4616-870E-3FF9DCE19F10Q35328058-BD8D2C3D-42E1-4DCC-B315-BA860252614FQ35393686-A1C95345-59B8-46C3-B8B4-A40ED34E903DQ36090305-F34529B1-FC99-4844-A364-D47D3CD3CD54Q36162037-44E89F1B-9951-4349-8807-C8027223D8F2Q36591347-1D037314-AA57-49AC-8B03-C5A4AAD20D49Q37190644-271F0673-5C33-4CD4-8342-7F6C74051796Q37282117-CFB0E848-7477-40A5-AD65-3C22CA894154Q37308001-A27E6E10-EED1-481E-AF6C-08FCBD9520EAQ37309725-D67C76F8-6035-467F-B47F-237A4C2973E9Q37423561-AFF56B26-B9E5-4E7E-BFA4-23F2C1BB5F42Q37423705-F0396F15-7EEF-4E31-9491-BDA03E5EAF50Q37522358-6ED98DD8-74C8-400E-9623-9C07752125D9Q37688604-2D474E33-8320-4D69-A8FD-03A7C1E602D3Q38133628-7FFB0057-3340-4970-95AD-F778669A41C6Q38616095-CB889CF4-C19C-4AF1-82B4-DC9D4ABE7C38Q38657429-65701C50-4F07-4FBE-AB45-68335CDE33AFQ39671780-E818456F-FEF0-4F18-9BA1-DA458370EDD9Q39842235-61A727D1-8947-45EB-9459-90A17A393632Q40073042-223FC549-80BC-48E2-B23F-426A1F50958AQ41306174-FF5A0E02-53DD-4AC6-96D6-AAC3B1104318Q42694571-A92F7428-74A5-470F-8C73-27CAD3B662D9Q44233870-354DF152-ADED-49DB-A5A5-4A97BB7801C6
P2860
Predictors of attrition during initial (citalopram) treatment for depression: a STAR*D report.
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Predictors of attrition during ...... r depression: a STAR*D report.
@ast
Predictors of attrition during ...... r depression: a STAR*D report.
@en
Predictors of attrition during initial
@nl
type
label
Predictors of attrition during ...... r depression: a STAR*D report.
@ast
Predictors of attrition during ...... r depression: a STAR*D report.
@en
Predictors of attrition during initial
@nl
prefLabel
Predictors of attrition during ...... r depression: a STAR*D report.
@ast
Predictors of attrition during ...... r depression: a STAR*D report.
@en
Predictors of attrition during initial
@nl
P2093
P50
P1476
Predictors of attrition during ...... r depression: a STAR*D report.
@en
P2093
A John Rush
Andrew A Nierenberg
Diane Warden
G K Balasubramani
Jonathan W Stewart
Lori Davis
Madhukar H Trivedi
Maurizio Fava
Sidney Zisook
Steven D Hollon
P304
P356
10.1176/APPI.AJP.2007.06071225
P407
P577
2007-08-01T00:00:00Z